Acta Neurochirurgica

, Volume 133, Issue 3–4, pp 184–190 | Cite as

Effects of vitamin D and retinoic acid on human glioblastoma cell lines

  • L. Magrassi
  • G. Butti
  • S. Pezzotta
  • L. Infuso
  • G. Milanesi
Experimental Research


The biological significance of vitamin D receptors expressed by glioblastoma and other glial tumours is still unclear. In an effort to clarify this issue we studied the effects of increasing concentrations of 25-dihydroxyvitamin D3 and its metabolite 1 α, 25-dihydroxyvitamin D3 on two human glioblastoma cell lines. Both substances were capable of inducing a significant (> 50%) reduction in growth of the two glioblastoma cell lines at dosages over 5 μM. When the HU 70 cell line was treated by increasing dilutions of 25-dihydroxyvitamin D3 combined with 1 μM all trans-retinoic acid, significant inhibition was apparent even after addition of 25-dihydroxyvitamin D3 in the nanomolar range. Reduction of growth index was mainly due to induced cell death.

Our results providein vitro evidence that vitamin D metabolites alone or in combination with retinoids may be potentially useful agents in the differentiation therapy of human malignant gliomas.


Glioblastoma retinoic acid vitamin D cell death 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abe E, Miyaura C, Sakagami H, Takeda M, Konno K, Yamazaki T, Yoshiki S, Suda T (1981) Differentiation of mouse myeloid leukemia cells induced by 1 α, 25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 78: 4990–4994PubMedGoogle Scholar
  2. 2.
    Albert DM, Marcus DM, Gallo JP, O'Brien JM (1992) The antineoplastic effect of vitamin D in transgenic mice with retinoblastoma. Invest Ophthalmol Vis Sci 33: 2354–2364PubMedGoogle Scholar
  3. 3.
    Baker AR, McDonnel DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, Pike JW, Shine J, Omalley BW (1988) Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 85: 3294–3298PubMedGoogle Scholar
  4. 4.
    Bower M, Colston KW, Stein RC, Hedley A, Gazet JC, Ford HT, Coombes RC (1991) Topical calcipotrid treatment in advanced breast cancer. Lancet 337: 701–702PubMedGoogle Scholar
  5. 5.
    Carlberg C, Bendik I, Wyss, Meier E, Sturzenbecker J, Grippo JF, Hunziker W (1993) Two nuclear signalling pathways for vitamin D. Nature 361: 657–660PubMedGoogle Scholar
  6. 6.
    Cheson BD (1992) The maturation of differentiation therapy. N Engl J Med 327: 385–387PubMedGoogle Scholar
  7. 7.
    Chomczynski P, Sacchi N (1987) Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156–159PubMedGoogle Scholar
  8. 8.
    Colston K, Colston MJ, Feldman D (1981) 1,25-Dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 108: 1083–1086PubMedGoogle Scholar
  9. 9.
    Committee on Enzymes of the Scandinavian Society for Clinical Chemistry and Clinical Physiology (1974) Recommended methods for the determination of four enzymes in blood. Scand J Clin Lab Invest 33: 191–306Google Scholar
  10. 10.
    Degos L (1993) Annual guest lecture, Leukemia Research Fund (UK): differentiation therapy and leukemia. Leukemia 7: 766–772PubMedGoogle Scholar
  11. 11.
    Della Valle G, Talarico D, Fognani C, Peverali AF, Raimondi E, De Carli L, Gerosa M (1989) Oncogene expression in human brain tumors. In: Broggi G, Gerosa MA (eds) Cerebral gliomas. Excerpta Medica, Amsterdam, pp 23–30Google Scholar
  12. 12.
    Eisman JA, Barkla DH, Tutton Pj (1987) Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res 47: 21–25PubMedGoogle Scholar
  13. 13.
    Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science 240: 889–895PubMedGoogle Scholar
  14. 14.
    Garland CF, Garland FC, Gorham ED (1991) Can colon cancer incidence and death rates be reduced with calcium and vitamin D3? Am J Clin Nutr 54: 193S-201SPubMedGoogle Scholar
  15. 15.
    Gerosa MA, Talarico D, Fognani C, Raimondi E, Colombatti M, Tridente G, De Carli L, Della Valle G (1989) Overexpression of N-ras oncogene and epidermal growth factor receptor gene in human glioblastomas. J Natl Canc Inst 81: 63–67Google Scholar
  16. 16.
    Hanauske A-R (1993) New approaches to chemotherapy of brain tumors with or without radiation. Crit Rev Neurosurg 3: 45–49Google Scholar
  17. 17.
    Hanchette Cl, Schwartz GG (1992) Geographical patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 70: 2861–2869PubMedGoogle Scholar
  18. 18.
    Kragballe K, Gjertsen BT, De Hoop D, Karlsmark T, van de Kerkhof PCM, Larko O, Nieboer C, Roed-Petersen J, Strand A, Tikjob G (1991) Double blind right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 337: 193–196PubMedGoogle Scholar
  19. 19.
    Langer A, Verjans H, Stapor V, Mol M, Fraczykowska M (1993) Topical calcitriol in the treatment of chronic plaque psoriasis: a double blind study. Br J Derm 128: 566–571Google Scholar
  20. 20.
    Lointier P, Wargovich MI, Saez S, Levin B, Wildrick DM, Boman BM (1987) The role of vitamin D3 in the proliferation of a human colon cancer cell line lovo in-vitro. Anticancer Res 7: 817–822PubMedGoogle Scholar
  21. 21.
    Magrassi L, Bono F, Butti G, Milanesi G (1992) Vitamin D receptor expression in human brain tumors. J Neurosurg Sci 36: 27–30PubMedGoogle Scholar
  22. 22.
    Magrassi L, Butti G, Silini E, Bono F, Paoletti P, Milanesi G (1993) The expression of genes of the steroid-thyroid hormone receptor superfamily in central nervous system tumors. Anticancer Res 13: 655–762PubMedGoogle Scholar
  23. 23.
    Matsumoto K, Azuma Y, Kiyoki M, Okumura H, Hashimoto K, Yoshikawa K (1991) Involvement of endogenously produced 1,25-dihydroxyvitamin D3 in the growth and differentiation of human keratinocytes. Biochem Biophys Ac 1092: 311–318Google Scholar
  24. 24.
    Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 65: 55–63PubMedGoogle Scholar
  25. 25.
    Nikkhah G, Tonn JC, Hoffmann O, Kraemer HP, Darling JL, Schonmayr R, Schachenmayr W (1992) The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part I: evaluation of test-specific variables J Neurooncol 13: 1–11PubMedGoogle Scholar
  26. 26.
    Noda M, Voge L, Craig AM, Prahl J, DeLuca H, Denhardt DT (1990) Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin d 3 receptor and 1,25-dihydroxyvitamin d 3 enhancement of mouse secreted phosphoprotein I (Spp-1 or osteopontine) gene expression. Proc Natl Acad Sci USA 87: 9995–9999PubMedGoogle Scholar
  27. 27.
    Okabe-Kado J, Honma Y, Kasukabe T, Hozumi M (1993) Synthesis of active metabolites from alpha-hydroxyvitamin D3 by human monocytic leukemia cells. FEBS-Lett 309: 399–401Google Scholar
  28. 28.
    Paoletti P, Walker MD, Takakura K, Butti G, Pezzotta S (eds) (1991) Neuro-Oncology. Kluwer, DordrechtGoogle Scholar
  29. 29.
    Posner GH, Nelson TD, Guyton KZ, Kensler TW (1992) New vitamin D3 derivatives with unexpected antiproliferative activity: 1-(hydroxymethyl)-25-hydroxyvitamin D3 homologs. J Med Chem 35: 3280–3287PubMedGoogle Scholar
  30. 30.
    Quigley MR, Maroon JC (1991) The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery 29: 385–389PubMedGoogle Scholar
  31. 31.
    Reichel H, Recker A, Deppisch R, Stier E, Ritz E (1992) 25-Hydroxyvitamin D3 metabolism in vitro by mononuclear cells from hemodialysis patients. Nephron 62: 404–412PubMedGoogle Scholar
  32. 32.
    Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74: 5463–5467PubMedGoogle Scholar
  33. 33.
    Schwartz Z, Brooks B, Swain L, Del Toro F, Norman A, Boyan B (1992) Production of 1,25-dihydroxyvitamin D3 and 24,25- dihydroxyvitamin D3 by growth zone and resting zone chondrocytes is dependent on cell maturation and is regulated by hormones and growth factors. Endocrinology 130: 2495–2504PubMedGoogle Scholar
  34. 34.
    Schwartz GG, Hulka BS (1990) Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anticancer Res 10: 1307–1312PubMedGoogle Scholar
  35. 35.
    Shany S, Ren SY, Arbelle JE, Clemens TL, Adams JS (1993) Subcellular localization and partial purification of the 25-hydroxyvitamin D3 1-hydroxilation reaction in the chick myelomonocytic cell line HD-11. J Bone Min Res 8: 269–276Google Scholar
  36. 36.
    Skowronski RJ, Peehl DM, Feldman D (1993) Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132: 1952–1960PubMedGoogle Scholar
  37. 37.
    Tanaka H, Abe E, Miyaura C, Kuribayashi T, Konno K, Nishii Y, Suda T (1982) 1α,25-dihydroxycholecalciferol and a human myeloid leukemia cell line (HL-60). Biochem J 204: 713–719PubMedGoogle Scholar
  38. 38.
    Thomas MG, Tebbut S, Wiliamson RCN (1992) Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. Gut 33: 1660–1663PubMedGoogle Scholar
  39. 39.
    Walters MA (1992) Newly identified actions of the vitamin D endocrine system. Endocrin Rev 13: 719–764Google Scholar
  40. 40.
    Wyllie AH, Kerr JFR, Currie AR (1980) Cell death: the significance of apoptosis. Int Rev Cytol 68: 251–306PubMedGoogle Scholar
  41. 41.
    Yung WKA, Lotan R, Lee P, Lotan D, Steck PA (1989) Modulation of growth and epidermal growth factor receptor activity by retinoic acid in human glioma cells. Cancer Res 49: 1014–1019PubMedGoogle Scholar
  42. 42.
    Yung WKA, Simaga M, Levin VA (1993) 13-cis-retinoic acid: a new and potentially effective agent for recurrent malignant astrocytomas. ASCO Proc 12: 175Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • L. Magrassi
    • 1
    • 2
  • G. Butti
    • 1
  • S. Pezzotta
    • 1
  • L. Infuso
    • 1
  • G. Milanesi
    • 2
  1. 1.Department of Surgery, Section of NeurosurgeryUniversity of PaviaPaviaItaly
  2. 2.IGBE CNRPaviaItaly

Personalised recommendations